ALTEOGEN Inc (KQ:196170) — Market Cap & Net Worth
Market Cap & Net Worth: ALTEOGEN Inc (196170)
ALTEOGEN Inc (KQ:196170) has a market capitalization of $12.26 Billion (₩18.09 Trillion) as of September 16, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #1898 globally and #40 in its home market, demonstrating a -9.09% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ALTEOGEN Inc's stock price ₩260000.00 by its total outstanding shares 69563175 (69.56 Million). Also see ALTEOGEN Inc (196170) total assets for a full breakdown of the balance sheet.
ALTEOGEN Inc Market Cap History: 2015 to 2026
ALTEOGEN Inc's market capitalization history from 2015 to 2026. Data shows growth from $259.94 Million to $12.26 Billion (46.56% CAGR). Also see cash efficiency ratio of ALTEOGEN Inc for how efficiently the company converts equity into cash flow.
Index Memberships
ALTEOGEN Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$231.82 Billion | 5.29% | #1 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$231.82 Billion | 5.29% | #1 of 1384 |
Weight: ALTEOGEN Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ALTEOGEN Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ALTEOGEN Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest ALTEOGEN Inc stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.10x
ALTEOGEN Inc's market cap is 0.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.15x
ALTEOGEN Inc's market cap is 0.15 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $214.43 Million | $6.84 Billion | -$3.59 Billion | 0.03x | N/A |
| 2017 | $290.71 Million | $12.10 Billion | -$7.45 Billion | 0.02x | N/A |
| 2018 | $374.52 Million | $13.70 Billion | -$6.87 Billion | 0.03x | N/A |
| 2019 | $876.05 Million | $29.23 Billion | -$704.51 Million | 0.03x | N/A |
| 2020 | $4.71 Billion | $42.43 Billion | -$969.60 Million | 0.11x | N/A |
| 2021 | $2.97 Billion | $41.12 Billion | $6.00 Billion | 0.07x | 0.50x |
| 2022 | $1.80 Billion | $28.81 Billion | -$8.15 Billion | 0.06x | N/A |
| 2023 | $4.64 Billion | $96.52 Billion | -$3.37 Billion | 0.05x | N/A |
| 2024 | $14.59 Billion | $102.85 Billion | $62.25 Billion | 0.14x | 0.23x |
| 2025 | $21.19 Billion | $215.86 Billion | $141.67 Billion | 0.10x | 0.15x |
Competitor Companies of 196170 by Market Capitalization
Companies near ALTEOGEN Inc in the global market cap rankings as of September 16, 2026. Review 196170 goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to ALTEOGEN Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
ALTEOGEN Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, ALTEOGEN Inc's market cap moved from $259.94 Million to $ 12.26 Billion, with a yearly change of 46.56%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩12.26 Billion | -42.16% |
| 2025 | ₩21.19 Billion | +45.23% |
| 2024 | ₩14.59 Billion | +214.21% |
| 2023 | ₩4.64 Billion | +157.52% |
| 2022 | ₩1.80 Billion | -39.37% |
| 2021 | ₩2.97 Billion | -36.81% |
| 2020 | ₩4.71 Billion | +437.22% |
| 2019 | ₩876.05 Million | +133.92% |
| 2018 | ₩374.52 Million | +28.83% |
| 2017 | ₩290.71 Million | +35.57% |
| 2016 | ₩214.43 Million | -17.51% |
| 2015 | ₩259.94 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of ALTEOGEN Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.26 Billion USD |
| MoneyControl | $12.26 Billion USD |
| MarketWatch | $12.26 Billion USD |
| marketcap.company | $12.26 Billion USD |
| Reuters | $12.26 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ALTEOGEN Inc
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the d… Read more